Compare Mesoblast Limited (MESO) vs State Street Technology Select Sector SPDR ETF (XLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs State Street Technology Select Sector SPDR ETF — how do they compare? Mesoblast Limited trades at $14.29 (market cap $1.75B), while State Street Technology Select Sector SPDR ETF trades at $198.78 (market cap $132.55B). The key difference: State Street Technology Select Sector SPDR ETF is far larger — about 75.7× Mesoblast Limited's market cap, and State Street Technology Select Sector SPDR ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and State Street Technology Select Sector SPDR ETF for 50 Days on average.
| MESO | XLK | |
|---|---|---|
Market Cap | $1.75B | $132.55B |
Volume | 239,027 | 9,063,135 |
Sector | Health | Sector/Thematic |
52-Week High | $20.96 | $202.00 |
52-Week Low | $13.19 | $127.49 |
Typical Hold Time | 15 Days | 50 Days |
Enterprise Value | $1.83B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.75, down 1.36% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $102.14 million in 2025, though revenue grew to $120 million in 2026. Recent milestones include FDA approval for a new potency assay and completion of a Phase 3 trial for chronic low back pain, signaling progress in its commercial pipeline.
The outlook is mixed; analyst consensus leans buy (45% buy ratings), but profitability remains a challenge with negative margins. Key risks include high cash burn and competitive pressures, while catalysts hinge on successful commercialization of RYONCIL and upcoming trial results. The stock presents a high-risk, high-reward opportunity in the biotech sector.
XLK trades at $197.79, down 1.79% on the day, with a bullish technical signal driven by moving averages. The ETF shows neutral oscillators and key support at $196. Recent news highlights concentration risks in its holdings, with some analysts favoring alternative tech ETFs for better diversification. Dividend activity is scheduled for late 2026.
Outlook remains cautiously optimistic given bullish technicals, but concentration in chip stocks poses a risk. Opportunities include AI-driven growth exposure, while risks involve interest rate sensitivity and sector-specific volatility. Investors should weigh diversification against growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About State Street Technology Select Sector SPDR ETF
XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.
Read more on XLK →
